Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort-Reference-Cited by-同舟云学术

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

Published:2023-07 Issue: Volume:53 Page:31-37
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Zschäbitz Stefanie,Biernath Nadine,Hilser Thomas,Höllein Alexander,Zengerling Friedemann,Cascucelli Jozefina,Paffenholz Pia,Seidl Daniel,Lutz Christoph,Schlack Katrin,Kingreen Dorothea,Klümper Niklas,Ivanyi Philipp,von Amsberg Gunhild,Heers Hendrik,Roghmann Florian,Tauber Robert L.,Cathomas Richard,Hofer Luisa,Niegisch Günter,Klee Melanie,Ehrenberg Roland,Hassler Andreas,Hadaschik Boris A.,Grünwald Viktor,Darr Christopher

Funder

Deutsche Forschungsgemeinschaft

Universität Heidelberg

Publisher

Elsevier BV

Subject

Urology

Reference15 articles.

1. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation;Takai;Nat Rev Mol Cell Biol,2008

2. Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction;Reymond;J Biol Chem,2001

3. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes;Hoffman-Censits;Appl Immunohistochem Mol Morphol,2021

4. Expression of nectin-4 in variant histologies of bladder cancer and its prognostic value-need for biomarker testing in high-risk patients?;Rodler;Cancers,2022

5. Tumor expression of nectin-1–4 and its clinical implication in muscle invasive bladder cancer: an intra-patient variability of nectin-4 expression;Miyake;Pathol Res Pract,2022

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

2. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer;Journal of Clinical Oncology;2024-07-10

3. Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study;Japanese Journal of Clinical Oncology;2024-06-29

4. Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center;Cancers;2024-06-18

5. Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience;Frontiers in Oncology;2024-06-12